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Abstract
Background: Circulating adiponectin (ADPN) levels are inversely associated with disease severity in patients with
chronic obstructive pulmonary disease (COPD), while studies assessing the relationship between ADPN and lung
function in subjects from the general population have shown diverging results. Accordingly, we hypothesized that
ADPN would be associated with lung function in a population-based sample and tested how abdominal adiposity,
metabolic syndrome, and systemic inflammation influenced this association.
Methods: We measured total ADPN in serum, forced vital capacity (FVC) and forced expiratory volume during the
1st second (FEV1) in 529 participants (median 50 years, 54.6% males) recruited from the general population. We
assessed the association between ADPN and lung function by multivariate linear regression analyses and adjusted
for age, gender, height, smoking habits, weight, body mass index, waist-hip ratio, metabolic syndrome, obstructive
sleep apnoea (OSA) and C-reactive protein.
Results: The median (interquartile range) level of serum ADPN was 7.6 (5.4–10.4) mg/L. ADPN levels were positively
associated with FVC % of predicted (beta 3.4 per SD adiponectin, p < 0.001)) in univariate linear regression analysis,
but the association was attenuated in multivariate analysis (standardized beta 0.03, p = 0.573)). Among co-variates
only WHR significantly attenuated the relationship. ADPN levels were also associated with FEV1% of predicted in
bivariate analysis that adjusted for smoking (beta 1.4, p = 0.042)), but this association was attenuated and no longer
significant in multivariate analysis (standardized beta -0.06, p = 0.254)).
Conclusion: In this population-based sample no association between ADPN and lung function was evident after
adjustment for covariates related to adiposity.
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Background
Chronic obstructive pulmonary disease (COPD) is a
heterogeneous disease characterized by chronic airway
inflammation and reduced lung function [1]. The effects
of current treatment options are modest, and COPD is
one of the leading causes of morbidity and mortality
worldwide [2]. Few serologic biomarkers are currently
available for guiding diagnosis, providing prognostic
information or evaluating treatment response in
COPD [3].
Among proposed serologic biomarkers is adiponectin
(ADPN); a protein abundant in serum, which is produced
in adipocytes, but also in other tissues including macro-
phages and airway epithelium [4]. ADPN levels have been
found to vary with age, gender, smoking, adiposity and the
presence of metabolic syndrome [5–7], some of which may
also influence pulmonary function [8]. ADPN is involved in
several physiological processes and predominantly exerts
anti-inflammatory effects [9, 10]. Previous observations in
COPD patients indicate that elevated ADPN levels are
associated with accelerated lung function impairment and
respiratory mortality [11–13]. In contrast, only limited and
contrasting results are currently available regarding the
association between ADPN levels and indices of lung func-
tion in subjects from the general population [14, 15].
Accordingly, we aimed to assess the association between
adiponectin and lung function in a general population sam-
ple. We hypothesized that we would find an inverse associ-
ation between ADPN levels and lung function. We also
aimed to assess the impact of adiposity, metabolic syn-
drome and systemic inflammation on the association
between ADPN levels and indices of lung function.
Methods
Study design and participants
This is a substudy of the Akershus Sleep Apnea Project
(ASAP), a two-phased clinical epidemiological study
designed to examine sleep apnea in a general population.
The recruitment protocol and inclusion/exclusion cri-
teria have previously been reported [16]. In brief, 30,000
subjects between 30 and 65 years, randomly drawn from
the Norwegian Personal Registry, received the Berlin
Questionnaire by mail in the first phase of the study
(Fig. 1). Among the 16,302 respondents, a clinical sam-
ple of 535 persons was drawn from pre-specified strata
based on equilibrium of age and gender, as well as 2/3 of
persons with at least 2 positive risk categories of the
Berlin Questionnaire [17].
The study was conducted in accordance with the
amended Declaration of Helsinki, and the Regional
Committee for Medical Research Ethics in Eastern
Norway approved the protocol (1.2005.839). We ob-
tained written informed consent from all participants
prior to study commencement.
Data collection
During an overnight hospital stay, the participants
underwent standardized data collection that included
medical history, clinical examination, venous blood sam-
pling, polysomnography and spirometry. Tobacco use
was categorized as current, former and never. Height,
weight, waist and hip circumference were recorded as
the mean of three measurements with less than 10%
variation, and were used to calculate the body mass
index (BMI; weight (kg)/ height [cm]2) and the
waist-hip-ratio (WHR). Lung function was assessed
by Spirosoft spirometry and CardioSoft software (GE
HealthCare, Munich, Germany) and recorded as the
best performance for forced vital capacity (FVC) and
forced expiratory volume during 1st second (FEV1)
from at least 3 attempts with < 15% variation. FEV1
and FVC in percent of predicted [18] were calcu-
lated and used as lung function variables in the ana-
lyses. Metabolic syndrome was defined according to
the National Cholesterol Educational Program cri-
teria [19], based on measurements of systolic blood
pressure, total cholesterol, low-density lipoprotein
cholesterol, glucose and WHR. Polysomnography was
performed and analyzed by two US board-certified
polysomnography technicians (Somnologica 3.2 soft-
ware package (Flaga-Medcare, Buffalo, NY, USA)).
Obstructive sleep apnoea (OSA) was defined as an
apnoea-hypopnoea index (AHI) equal to or higher
than five.
Biochemical analysis
Venous blood samples were collected in the fasting state
in the morning, immediately prepared by centrifugation
Fig. 1 Study flow in the Akershus Sleep Apnea Project
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and separation into plasma and serum samples that were
frozen at − 20 °C for a maximum of 1 week before stored
at − 80 °C pending analyses, as previously reported [20].
Serum ADPN was determined by a validated in-house
time-resolved immunofluorometric assay as previously
described [21]. All samples were analyzed in duplicate,
with a detection limit of 1.5 μg/L and intra- and interas-
say coefficients of variation < 5% and < 7%, respectively.
C-reactive protein (CRP) was analyzed by a highly sensi-
tive latex immunoassay-kit on a COBAS INTEGRA400
(Roche), with a lower detection limit of 0.1 mg/L.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or
median (quartile [Q] 1–3) for data with a non-normal
distribution. We grouped the participants into tertiles of
serum ADPN levels and used one-way analysis of vari-
ance, Kruskal-Wallis test or chi-square tests to compare
clinical data between the groups. We applied multivari-
ate linear regression to explore the association between
ADPN and chosen covariates. Linear regression was also
used to examine the univariate association between lung
function and ADPN, as well as the covariates smoking
status, weight, BMI, WHR, metabolic syndrome and
CRP. We used FEV1 and FVC in percent of predicted as
dependent variables, thus, additional adjustment for the
covariates age, gender, ethnicity and height were not
considered. The multivariate analyses were performed in
two stages; we first added adiposity variables, metabolic
syndrome and CRP one-by-one to separately evaluate
the impact of these features on the association between
ADPN and lung function. In the final multivariate linear
regression analysis all covariates were first entered sim-
ultaneously followed by a stepwise removal of the covar-
iate with the highest p-value until all covariates were
significantly associated with lung function. Adiponectin
was kept in all steps independently of p-value. All re-
gression models were assessed for collinearity. The stat-
istical analyses were performed with Statistical Package
for Social Sciences 22, and a p-value < 0.05 was regarded
as statistical significant.
Results
The median (Q 1-3) ADPN level in the total population
was 7.6 (5.4–10.4) mg/L. Indices of lung function, demo-
graphic and clinical characteristics, and laboratory data
of the participants are presented stratified according to
tertiles of serum ADPN concentrations in Table 1.
The absolute values of FEV1 and FVC decreased by
increasing ADPN tertiles. For FEV1% of predicted, there
was no significant difference between ADPN tertiles,
while FVC% of predicted increased by increasing ADPN
levels (Fig. 2). Age and proportion of females increased
across tertiles of serum ADPN, while height, weight,
BMI, WHR, CRP and the proportion of participants with
metabolic syndrome decreased. Smoking status and
prevalence of OSA did not differ significantly between
the groups. Univariate and multivariate analysis of the
association between ADPN and selected covariates are
shown in Additional file 1: Table S1. All variables except
smoking were significantly correlated with ADPN in uni-
variate analysis, while age, gender, WHR and metabolic
syndrome remained significantly associated with ADPN
in multivariate analyses.
The crude associations between FEV1 or FVC % of
predicted and ADPN, smoking status, anthropometric
parameters, metabolic syndrome, OSA and CRP are
shown in Table 2.
There was no significant association between FEV1%
of predicted and ADPN. A positive association with
ADPN was found after adjustment for smoking, while
the models including each of the other co-variates found
no associations between FEV1% of predicted and ADPN.
In contrast, FVC% of predicted was significantly associ-
ated with ADPN, measures of adiposity, metabolic syn-
drome, OSA and CRP, but not with smoking. The
association between ADPN and FVC in % of predicted
remained positive after adjusting for smoking status,
weight, BMI, metabolic syndrome, OSA and CRP one by
one in separate linear regression models. However, the
association was attenuated and no longer significant
when adjusting for WHR (Table 3).
In the final multivariate models that included smoking
status, BMI, WHR, metabolic syndrome, OSA and CRP,
ADPN was not associated with any of the lung function
variables (Table 4).
Discussion
In the present population-based sample, we found that
ADPN was positively associated with lung function after
adjustment for age, gender, height and smoking, but this
association was attenuated and not significant when
adjusting also for indices of adiposity, metabolic syn-
drome, CRP and OSA. This result reflects the negative
impact of adiposity on both lung function and serum
ADPN levels.
The negative association between ADPN and severity
of COPD previously observed in clinical cohorts has no
established pathophysiological explanation, but could
imply that ADPN is linked to disease development and
progression. In the present study, we investigated
whether a negative association between ADPN and lung
function was present in a Caucasian general-population
sample, hypothetically reflecting ADPN as an early
marker of obstructive airway limitation. The two previ-
ous population-based studies assessing the relationship
between ADPN and lung function have reported diver-
ging results. A Japanese study reported a negative
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association between ADPN and FEV1/FVC in unadjusted
analyses, as well as accelerated decline in FEV1 with
higher ADPN levels after adjustment for age, gender,
height, smoking and BMI. In contrast, the CARDIA
study, like the present study, observed an inverse associ-
ation between ADPN and lung function in unadjusted
analyses, but this association was attenuated and no lon-
ger significant in analysis that adjusted also for insulin
resistance and systemic inflammation [14]. Thus, we find
it plausible that circulating ADPN levels are primarily
associated with indices of adiposity, and that univariate
associations between ADPN levels and pulmonary func-
tion reflect an inverse association between adiposity and
pulmonary function.
A novel finding in the present study is the important
role of WHR as a confounder in the association between
ADPN and lung function. While previous studies and
the present study found that BMI alone did not attenu-
ate the association between ADPN and lung function,
WHR alone attenuated the association between ADPN
and FVC in the present study. WHR also remained sig-
nificantly associated with both FEV1% of predicted and
FVC % of predicted in multivariate analysis. Abdominal
adiposity is a surrogate marker of visceral adiposity and
is associated with serum levels of adiponectin, metabolic
disease and systemic inflammation, but also results in
mechanical restriction that may affect lung function and
Fig. 2 Lung function in % of predicted according to tertiles
of adiponectin
Table 1 Characteristics of the participants according to tertiles of serum adiponectin levels
ADPN tertiles
Variables Total Tertile 1 Tertile 2 Tertile 3 p
n = 529 n = 176 n = 176 n = 177
ADPN, mg/Ld 7.6 (5.4, 10,4) 4.6 (3.8, 5.4) 7.6 (6.7, 8.3) 12.6 (10.3, 15.4) N/A
Age, years 48.6 (11.3) 46.4 (11.2) 48.6 (10.9) 50.7(11.0) 0.002a
Female gender 240 (45.4) 40 (22.7) 74 (42.0) 126 (71.2) < 0.001b
Height, cm 173 (9) 176 (8) 174 (9) 170 (8) < 0.001a
Smoking status 0.860b
Current smokers 138 (26.8) 45 (25.9) 50 (29.1) 43 (25.4)
Previous smokers 184 (35.7) 64 (36.8) 62 (36.0) 58 (31.5)
Never smokers 193 (37.5) 65 (37.4) 60 (34.9) 68 (40.2)
Weight, kg 86.7 (17.3) 94.2 (15.4) 88.3 (17.2) 77.6 (15.2) < 0.001a
BMI, kg/m2 28.9 (4.98) 30.5 (4.6) 29.2 (5.0) 26.9 (4.6) < 0.001a
WHR 0.94 (0.1) 0.99 (0.08) 0.95 (0.09) 0.88 (0.09) < 0.001a
Metabolic syndrome 174 (32.9) 89 (50.6) 58 (33.0) 27 (15.5) < 0.001b
OSA 293 (55.6) 71 (30.3) 75 (32.1) 88 (37.6) 0.167b
CRP, mg/Ld 1.26 (0.65, 2.94) 1.48 (0.78, 3.20) 1.44 (0.69, 3.28) 0.92 (0.50, 2.09) 0.001c
FEV1 3.41 (0.88) 3.64 (0.89) 3.51 (0.93) 3.09 (0.77) < 0.001
c
FVC 4.15 (1.03) 4.37 (0.99) 4.27 (1.08) 3.81 (0.93) < 0.001c
FEV1, % of predicted 103.25 (16.11) 101.19 (16.11) 104.45 (16.66) 104.09 (15.44) 0.115
a
FVC, % of predicted 103.96 (16.33) 99.52 (15.78) 104.79 (16.22) 107.53 (16.05) < 0.001a
ADPN adiponectin, FEV1 forced expiratory volume during 1st second, FVC forced vital capacity, BMI body mass index, WHR waist-hip ratio, OSA obstructive sleep
apnoea, CRP C-reactive protein
aanalyses of variance, bchi-square tests, cKruskal-Wallis
Continuous variables are expressed as mean (standard deviation) or dmedian (interquartile range) and categorical variables are expressed as number (%).
Metabolic syndrome is defined according to the National Cholesterol Education Program criteria. OSA, Obstructive Sleep apnoea is defined as apnoea-hypopnoea
index ≥5
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FVC in particular. The results from the present study
indicate that the role of mechanic restriction from ab-
dominal obesity contributes more to lung function than
the changes in ADPN secretion and metabolic disease
associated with this condition,
Interestingly, there were differences between FEV1 and
FVC in % of predicted as dependent variables. While
FVC is a measure of lung volume, FEV1 is also an indi-
cator of airway obstruction. In our study, ADPN was
only associated with FVC % of predicted in univariate
analyses. Also, while all types of adiposity-related factors
further attenuated the association between ADPN and
FEV1% of predicted, only WHR attenuated the positive
association between FVC % of expected and ADPN. This
might reflect that CRP and metabolic syndrome, as indi-
cators of inflammatory and metabolic consequences of
adiposity, are more important for FEV1 than for FVC.
This is in accordance with results in the CARDIA-study,
which found metabolic syndrome and insulin resistance
as well as systemic inflammation to attenuate the
relationship between FEV1 and adiponectin. These fac-
tors will be important to include in multivariate analysis
when evaluating the relationship between ADPN and
lung function.
There are several differences in the three presented
population-based studies, besides the choice of covari-
ates, which could explain the discrepant conclusions.
One factor that could impact the result is ethnic varia-
tions with our study including primarily Caucasian sub-
jects, the CARDIA study including a mixed American
population while the third study examined a Japanese
population. The CARDIA study also included younger
individuals (mean age 40 years), the present study sub-
jects with mean age of 50 years, and the Japanese study
subjects with mean age of ~ 60 years. As ADPN levels
are known to increase with age [22], different age groups
could potentially also contribute to the diverging results
between these three general population-based cohorts.
A limitation compared to previous studies is the
cross-sectional design that makes us unable to
Table 3 The associations between adiponectin (ADPN) and lung function in percent of predicted adjusting for different covariates
one by one
Unstandardized beta (95% CI) ADPN (per SD)
FEV1% of predicted p FVC % of predicted p
Unadjusted 1.012 (− 0.365, 2.388) 0.149 3.414 (2.047, 4.781) < 0.001
Adjusted for Weight (per 5 kg) 0.060 (− 1.445, 1.566) 0.937 2.166 (0.681, 3.651) 0.004
BMI 0.303 (− 1.139, 1.744) 0.680 2.658 (1.229, 4.087) < 0.001
WHR − 1.213 (− 2.771, 0.345) 0.127 0.425 (− 1.085,1.935) 0.581
Current smoking 1.393 (0.048, 2.739) 0.042 3.556 (2.172, 4.941) < 0.001
Previous smoking 1.380 (0.017, 2.742) 0.047 3.529 (2.141, 4.917) < 0.001
Metabolic syndrome 0.353 (−1.078, 1.785) 0.628 2.610 (1.195, 4.025) < 0.001
OSA 1.090 (−0.299, 2.480) 0.124 3.282 (1.90, 4.664) < 0.001
CRP(per SD) 0.834 (−0.537, 2.206) 0.232 3.262 (1.897, 4.626) < 0.001
FEV1 forced expiratory volume during 1st second, FVC forced vital capacity, CI confidence interval, ADPN adiponectin, BMI body mass index, WHR waist-hip ratio,
OSA obstructive sleep apnoea, CRP c-reactive protein
Table 2 Univariate associations between lung function expressed as FEV1 and FVC in percent of predicted, adiponectin, smoking
status, indices of adiposity, metabolic syndrome, obstructive sleep apnoea and C-reactive protein
FEV1% predicted FVC % predicted
Unstandardized beta (CI) p Unstandardized beta (CI) p
ADPN (per SD) 1.012 (− 0.365, 2.388) 0.149 3.414 (2.047, 4.781) < 0.001
Current smoking −5.444 (−8.483, − 2.406) < 0.001 −2.219 (−5.410, 0.972) 0.173
Previous smoking 0.645 (− 2.197, 3.487) 0.656 − 1.143 (−4.096, 1.811) 0.448
Weight (per 5 kg) −0.661 (− 1.055, − 0.268) 0.001 − 1.119 (− 1.510, − 0.728) < 0.001
BMI kg/m2 −0.466 (− 0.740, − 0.192) 0.001 −0.647 (− 0.922, − 0.371) < 0.001
WHR −38.297 (− 52.041, − 24.553) < 0.001 −62.199 (−75.488, − 48.909) < 0.001
Metabolic syndrome −4.905 (−7.808, − 2.001) 0.001 − 7.375 -10.289, − 4.471) < 0.001
OSA −2.143 (− 4.911, 0.625) 0.129 − 3.923 (− 6.725, − 1.120) 0.006
CRP (per SD) − 2.157 (− 3.524, − 0.791) 0.002 − 2.071 (− 3.457, − 0.685) 0.003
FEV1 forced expiratory volume during 1st second, FVC forced vital capacity, CI confidence interval, ADPN adiponectin, SD standard deviation, BMI body mass index,
WHR waist-hip ratio, OSA obstructive sleep apnoea, CRP C-reactive protein
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evaluate changes in lung function and causal path-
ways. On the other hand, compared to CARDIA, we
were able to analyze ADPN samples obtained at the
same time point as the spirometry. The ASAP cohort
consisted of individuals with more risk factors for ob-
structive sleep apnoea than a strict general population
sample and were as a group more obese, more sleepy
and had a higher rate of diabetes and prior myocar-
dial infarction than the general population sample
responding to the Berlin questionnaire in the first
part of the study. OSA is associated with lower
ADPN levels and is a possible confounder in the ex-
amined relationship between ADPN and lung func-
tion. However, the prevalence of OSA did not differ
between the tertiles of ADPN and the association be-
tween FVC% of predicted and ADPN remained sig-
nificant after adjustment for OSA and metabolic
syndrome. Also mean ADPN levels and measures of
lung function in the study sample were comparable
to those observed in previous general population
studies [15, 23]. Based on this we believe our results
are valid also for subjects from the general popula-
tion. Finally, only total ADPN levels were measured
and therefore information regarding different isoforms
is not available.
Conclusions
In this population-based study, we found a positive as-
sociation between ADPN and FEV1 and FVC after ad-
justment for age, gender, height and smoking that was
attenuated after additional adjustment for indices of
abdominal adiposity. Accordingly, future assessment
of the association between ADPN and lung function
should take both multiple indices of adiposity and its
metabolic consequences into consideration.
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